Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
Protein kinase C inhibitors and methods of their use
US9452998B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9452998-B2 |
| Application number | US-201514818778-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 5, 2015 |
| Priority date | Aug 6, 2014 |
| Publication date | Sep 27, 2016 |
| Grant date | Sep 27, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound that is selected from: or a pharmaceutically acceptable salt thereof. 2. A compound according to claim 1 that is: or a pharmaceutically acceptable salt thereof. 3. A compound according to claim 1 that is: or a pharmaceutically acceptable salt thereof. 4. A compound according to claim 1 that is: or a pharmaceutically acceptable salt thereof. 5. A pharmaceutically acceptable salt of the compound according to claim 2 . 6. A pharmaceutically acceptable salt of the compound according to claim 3 . 7. A pharmaceutically acceptable salt of the compound according to claim 4 . 8. A pharmaceutical composition comprising a compound that is selected from: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. 9. A pharmaceutical composition according to claim 8 comprising the compound or a pharmaceutically acceptable salt thereof. 10. A pharmaceutical composition according to claim 8 comprising the compound or a pharmaceutically acceptable salt thereof. 11. A pharmaceutical composition according to claim 8 comprising the compound or a pharmaceutically acceptable salt thereof. 12. A method of treating uveal melanoma comprising administering a compound selected from: or a pharmaceutically acceptable salt thereof, to a subject in recognized need thereof. 13. The method according to claim 12 , wherein the compound is or a pharmaceutically acceptable salt thereof. 14. The method according to claim 12 , wherein the compound is or a pharmaceutically acceptable salt thereof. 15. The method according to claim 12 , wherein the compound is or a pharmaceutically acceptable salt thereof. 16. The method according to claim 12 , wherein the uveal melanoma is treated in a subject harboring GNAQ mutations. 17. The method according to claim 12 , wherein the uveal melanoma is treated in a subject harboring GNA11 mutations. 18. The method according to claim 12 , wherein the compound or pharmaceutically acceptable salt thereof is administered in combination with at least one additional therapeutic agent.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- C07D401/14Primary
containing three or more hetero rings · CPC title
not condensed and containing further heterocyclic rings · CPC title
Antineoplastic agents · CPC title
Antibacterial agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9452998B2 cover?
- PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
- Who is the assignee on this patent?
- Visser Michael Scott, Luzzio Michael Joseph, Papillon Julien, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).